Stocks to sell

Nio (NYSE:NIO) stock has an awful lot riding on its upcoming earnings report. Source: Sundry Photography / Shutterstock.com For any publicly traded company, earnings reports are critical as they present a showcase for stakeholders and prospective buyers. But for Nio, the financial disclosure for the second quarter will truly determine whether people can trust its

Bionano (NASDAQ:BNGO) is a small life sciences company. Biotech companies use Bionano’s Saphyr system for researching DNA and to diagnose illnesses caused by genetics. Up until recently, Bionano has had difficulty achieving widespread market adoption for Saphyr. However, BNGO stock has gone on a wild ride over the past year as traders gravitated to Bionano’s

At one point, Zomedica (NYSE:ZOM) could do no wrong. ZOM stock would explode some 2,900% from its November 2020 lows. The company was nearing commercialization of its point-of-care diagnostic product. Even the pet industry was howling about the opportunity. Source: Postmodern Studio / Shutterstock.com Nowadays, Zomedica has become a slow-motion train wreck. In fact, the last

In a matter of weeks, DiDi Global (NYSE:DIDI) stock has gone from a hot IPO to an undeniable disaster. Soon after its debut on the U.S. stock market at an initial price of $14 per share, the China-based ride-hailing company was hit hard by the  Chinese government’s decision to investigate and penalize it. The shares

With Covid-19 vaccination rates slowing around the world, now is not the time to buy biotechnology company Novavax (NASDAQ:NVAX) stock. Source: Ascannio/Shutterstock.com NVAX stock fell 10% between July 20 and July 27 as hope fades that the company will be able to get its Covid-19 vaccine to market in time to capitalize on demand for

Over the last few weeks, there have been more than enough reasons to be skeptical about the record-breaking run in equities. Recently, I’ve been harping on the ridiculous amount of speculation in the market. But even more problematic is the Covid-19 pandemic. Just when you thought the crisis was fading into the rearview mirror, cases

A decade ago, after returning to finance from 30 years covering computer technology, I got into an argument over a company called Dendreon. You’ll see why this lingering thoughts connects me to BIIB stock below. Source: PictureDesignSwiss / Shutterstock.com Dendreon had launched a treatment for prostate cancer called Provenge. It is an immunotherapy, tied to

GameStop (NYSE:GME) stock has been one of 2021’s most incredible investing stories. The initial short squeeze was incredible to watch. Few market analysts could have ever imagined that a struggling mall retailer like GameStop could see its shares surge thousands of percent. Source: rblfmr / Shutterstock.com That surge, in turn, saved the company. GameStop raised

Other than a short-lived rally in June fueled by Reddit users, ContextLogic (NASDAQ:WISH) stock is on a permanent trajectory downward. Source: sdx15 / Shutterstock.com WISH stock peaked at $32.85, shortly after its initial public offering earlier this year. The company’s unfavorable valuations, mixed first-quarter results, and poor sales forecast continue to weigh on its share

Shares of digital marketing platform Marin Software (NASDAQ:MRIN) have been on a rollercoaster of late. MRIN stock was trading at $3.50 on June 24 and shot up to highs of $27 in the first week of July. It has surged in popularity due to the growing retail trading interest in the stock and news of its

Hey, cut me some slack. I would have written about ContextLogic’s (NASDAQ:WISH) Chief Financial Officer (CFO) resigning from his position in late June, but I only got the opportunity to write about WISH stock in the dog days of July. Source: sdx15 / Shutterstock.com Rajat Bahri’s last day as CFO was July 23. In his

Zomedica (NYSEAMERICAN:ZOM) might be in some sort of trouble with the launch of its new TruForma diagnostic machine. That is why ZOM stock has been falling and will likely keep dropping in the days ahead. Source: Postmodern Studio / Shutterstock.com Here is the likely reason. On May 14, 2021, Dr. Stephanie Morley resigned as its

It’s been a wild month for investors in the company formerly known as Torchlight Energy. Torchlight traded as TRCH stock and sought to develop its Hazel property into a major oil play. Source: FreezeFrames / Shutterstock.com However, Hazel didn’t end up striking it rich, and Torchlight looked to exit the oil and gas business. Instead,

Torchlight Energy Resources and TRCH stock are now history. How so? Well, the company recently merged with Metamaterials to form the new Meta Materials (NASDAQ:MMAT) stock. Source: Shutterstock However, it’s not as simple as that. Rather, TRCH stock has made a lot of news lately and moved way  too fast. Further, the mix of news

With DiDi Global (NYSE:DIDI) in the crosshairs of the Chinese government, there is a significant chance that the company’s business will be crippled or even shut down. At the very least, Didi’s growth is likely to be meaningfully hindered for a very long time. As a result of these points, I strongly urge investors to

When it comes to stocks, I tend to be a glass-half-full kind of person, which is why I don’t often write about stocks to sell.  Alas, you can run, but you can’t hide. So I’ve been asked to come up with 10 names I feel investors ought to jettison before they crash and burn.  What

No matter how the novel coronavirus pandemic pans out from here, more than likely, history will regard Novavax (NASDAQ:NVAX) stock as a Cinderella tale. Source: Ascannio/Shutterstock.com Just a year before Novavax earned a $1.6 billion award from the Trump administration’s Operation Warp Speed initiative, the company was on the verge of collapse. Then, seemingly out

In all my articles about stocks on InvestorPlace, I save my investment thesis for the end. But for GameStop (NYSE:GME), let me be upfront: I do not like the stock, its fundamentals or certainly its lofty price. Source: rblfmr / Shutterstock.com There are many good stocks listed on the U.S. stock exchanges, and many of them

Inarguably, one of the current century’s biggest investment narratives has been the rise of China stocks. Once a mess of an economy suffering from an identity crisis, the Asian juggernaut embraced Western-style capitalism — at least in its business dealings. Quickly, the so-called Chinese miracle occurred, catapulting the nation to an economic powerhouse second only

Krispy Kreme (NASDAQ:DNUT) just went public again for the second time, when its private equity owner JAB Holding sold less than 20% of its shares to the public at $17. Unfortunately, most of the money will just be used to reduce the company’s debt. DNUT stock will is still trading at a high Enterprise Value